乌鸦传媒視頻

Absolute difference of 4.9% at 5 years, including a benefit for patients who did not achieve pCR

Potential new option for patients with previously treated extrapancreatic or pancreatic NETs

Results "practice-changing," says expert

Adding lenvatinib, pembrolizumab to TACE significantly improved PFS, numerically improved OS

Hazards for radiographic PFS, OS reduced by 31% with enzalutamide plus Ra-223

POD1UM-303/InterAACT 2 data also trend in the direction of better overall survival

But combination may be appropriate for shrinking tumors before surgery

Second-line T-DXd best option in patients with and without intracranial activity, experts says

Data support that ICI rechallenge should be discouraged in patients with advanced RCC

Follow-up results from phase II study show 12-month EFS rate of 89% in stage II-IV disease

Time to radiographic progression doubled with ¹⁷⁷Lu-PSMA-617

Amivantamab-based regimens improved oncologic outcomes, but with more side effects

Adjuvant alectinib reduces disease-free survival hazard by 76%

Still some unanswered questions about benefit over other drug regimens, expert says